Centre For Research Excellence In Malaria Elimination
Funder
National Health and Medical Research Council
Funding Amount
$2,470,291.00
Summary
The CRE will work to accelerate progress towards malaria elimination in our region, through Surveillance, to develop better ways to monitor malaria transmission and discover who is infected, and to track movement of malaria parasites and spread of drug resistance. Diagnosis, to develop and test new, more sensitive ways of detecting malaria. Treatment, to fast track development of new antimalarials, and improve access to ensure all infected people get highly effective drugs.
TB is a global public health problem, responsible for the deaths of 2 million children and young adults annually. Drug resistant strains of TB are emerging and pose a threat even in countries where TB is well controlled, such as Australia. Research undertaken in this CRE will translate into improved treatments, diagnostics and strategies to prevent transmission. The CRE will build capacity for research on TB in our region and provide a legal framework to support public health policy.
Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Centre Of Research Excellence - REduce The Burden Of Antimicrobial ReSistance Through OPtimal, PersONalised Dosing (RESPOND)
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
Each year more than 17 million people die from infectious diseases. Many of these deaths are due to the poor use of antimicrobial drugs and an increase in infections caused by antimicrobial-resistant 'superbugs'. CRE RESPOND will enable an optimal treatment of infection by empowering clinicians with an evidence-based, patient-centred approach to guide antimicrobial dosing. We will generate new knowledge, educate healthcare workers, and build research capacity through our network of collaborators
Australian Centre For Cannabinoid Clinical And Research Excellence (ACRE): Quality And Safety In The Implementation Of Medicinal Cannabis Use In The Community
Funder
National Health and Medical Research Council
Funding Amount
$2,498,471.00
Summary
Australia has a world-first opportunity to develop rigorous medical cannabis research based on quality clinical and environmental science that tests and selects cannabis constituents affecting health and sickness. It will be able to design and coordinate dose and formulation-finding studies to assess safety and efficacy of different cannabinoids. This information will enable registration of products for health that have been thoroughly researched and tested to levels acceptable for public use.
A National Centre For Antimicrobial Stewardship: Using A One Health Approach
Funder
National Health and Medical Research Council
Funding Amount
$2,601,801.00
Summary
The emergence of antimicrobial resistance is a serious worldwide problem. The National Centre for Antimicrobial Stewardship will use a One Health approach to address antibiotic use in both humans and animals. We will focus on hospitals, aged care, and general practice. In animal health, we will investigate links between antibiotic use in animal production and resistant bacteria, and evaluate usage in companion animals. The aim is to promote appropriate antibiotic use in animal and human health.
Centre For REdefining Antibiotic Use To ReDUce ResistanCE And Prolong The Lives Of Antibiotics (REDUCE)
Funder
National Health and Medical Research Council
Funding Amount
$2,158,296.00
Summary
Ineffective dosing of antimicrobials has contributed to the escalation of antimicrobial resistance which now pervades the healthcare system. Patients in the intensive care unit and post-transplant are examples of patients who commonly have infections, are more likely to fail treatment and have resistant microbes emerge. In these studies we will characterise the doses of antimicrobials that should be used in these difficult-to-treat patients and rapidly share these for routine clinical use.
Centre Of Research Excellence In Medicines And Ageing
Funder
National Health and Medical Research Council
Funding Amount
$2,601,415.00
Summary
Medicines have an important place in health and are commonly used for long periods, sometimes life-long. Using medicines wisely requires a careful balance between benefits and harmful effects. Currently, there is limited information to guide medicines use over a lifetime. Using large linked datasets, the CRE in Medicines and Ageing will generate much needed evidence about real world medicines use to support clinical and pharmaceutical policy decisions.
Mental and substance use disorders account for more years of life lost due to disability than any other disorders. These disorders often occur together (comorbidity), yet, people with both mental and substance use disorders rarely have both disorders effectively treated. This CRE is a world first, tackling prevention and treatment for people with both mental and substance use disorders.
National Centre For Research Excellence In Neuromuscular Disorders: Transforming The Management Of Neuromuscular Disorders From Compassionate Assistance To Targeted Therapy And Prevention
Funder
National Health and Medical Research Council
Funding Amount
$2,805,509.00
Summary
Neuromuscular disorders affect 1 in 1,000 people, often result in progressive muscle weakness and can cause early death. At present not enough is being done to ensure translation of research into improved outcomes for patients. For the first time in Australia, the CRE-NMD will establish an integrated, comprehensive program to investigate diagnosis, prevention and treatment of neuromuscular disorders from infancy to adulthood.